Tools   Select Another Resource Report Type

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=66742&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 03, 2014. A study that is a follow-up of the CATSS study and includes 15-year old twins who have been identified with autism, ADHD, learning-, eating-, tics disorders, compulsion-, defiance-, conduct- or motor control problems. The study also includes the co-twin, controls and the parents. DNA will be collected from the twins and the parents. For the twins, both a saliva sample and capillary blood samples will be collected, and for the parents, a saliva sample will be collected. Types of samples * Saliva alt. capillary blood * DNA Number of sample donors: 764 (June 2010)

Proper citation: DOGSS (RRID:SCR_005946) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/HuREF/?SsId=78

The Human Reference Genetic Material Repository makes available DNA from a single individual, J. Craig Venter, whose genome has been sequenced and assembled. The DNA samples are prepared from a lymphoblastoid cell line established at Coriell Cell Repositories from a sample of peripheral blood. The DNA samples are available in 50 microgram aliquots. The lymphoblastoid cell line is not available for distribution. The human DNA sample provided is that of J. Craig Venter whose DNA from white blood cells and sperm was sequenced using Sanger chemistry (ABI Capillary Electrophoresis Platforms 3700 and 3730xl), assembled using the Celera Assembler and was published in PLoS Biology . J. Craig Venter, born on 14 October 1946, is a Caucasian male of self-reported European-American ancestry. The data available on this sample, whose genome assembly is referred to as HuRef, includes: * Whole Genome Shotgun Sequencing data * Sequence trace set deposited by JCVI in the NCBI trace archive * Human Genome Browser displaying sequence assembly, DNA variants and gene annotations Additional data sets from this study include: * Full set of Sanger reads used for genome assembly * SNP and insertion/deletion variant on the human genome sequence coordinates (NCBI version 36) * Affymetrix 500K GeneChip data * Illumina HumanHap650Y Genotyping BeadChip data Given the amount of data publicly available the genomic content of this sample, HuRef will be useful as a reference for many genetic studies.

Proper citation: Human Reference Genetic Material Repository (RRID:SCR_004693) Copy   

•   Source: SciCrunch Registry

http://www.spaintechnology.com/biotech/news/hiv-biobank.html

THIS RESOURCE IS NO LONGER IN SERVICE, documented on September 15, 2011. The Spanish HIV BioBank was created with the objectives of processing, storing and providing distinct samples from HIV/AIDS patients, categorized according to strictly defined characteristics, free of charge to research projects. Strict compliance to ethical norms is always guaranteed. HIV BioBank possesses nearly 50,000 vials containing different prospective longitudinal study sample types. More than 1,700 of these samples are now used in 19 national and international research projects. (2009) The HIV BioBank represents a novel approach to HIV research that might be of general interest not only for basic and clinical research teams working on HIV, but also for those groups trying to establish large networks focused on research on specific clinical problems. It also represents a model to stimulate cooperative research among large numbers of research groups working as a network on specific clinical problems. The HIV BioBank is able to very efficiently release samples to different research project not only in Spain but also in other countries.

Proper citation: HIV Biobank (RRID:SCR_004691) Copy   

•   Source: SciCrunch Registry

http://www.mssm.edu/research/institutes/institute-for-personalized-medicine/biobank

The Mount Sinai Biobank is a large collection of DNA and plasma samples that are stored in a way that protects patients'' privacy while allowing research to be performed on de-identified clinical information from Mount Sinai''s data warehouse system. The Biobank''s goal is to acquire samples from a total of 100,000 donors over a period of several years. Mount Sinai is one of only a handful of places nationwide establishing biobanks on such a large scale. Funded by the Charles R. Bronfman Institute for Personalized Medicine, the Biobank project is a research project that is approved by the Mount Sinai Institutional Review Board and is continuously reviewed. Biobank Facts: * 17947 donors between 18 and 89 years of age have already participated in Biobank. * 194111 aliquots of DNA and * 212005 aliquots of plasma are available for future research.

Proper citation: Mount Sinai Biobank (RRID:SCR_004845) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=31618&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. The aim of the study is to estimate the importance of genetic (primary) and environmental factors for economic behavior by conducting a series of standard behavioral economics experiments on a sample of twins from the Swedish Twin Registry.

Proper citation: KI Biobank - Economical Behavior (RRID:SCR_005934) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29358&a=31596&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. So far there is only limited knowledge about possible genetic influences in acute spinal cord injuries (SCI). In this project DNA is collected prospectively from persons with SCI admitted to the acute SCI rehabilitation unit of the Karolinska University Hospital. Trauma is the cause of injury in a majority of the patients. Other causes of injury are spinal abscesses, tumors or spinal infarctions. The aim of the project is to create a sufficiently large DNA biobank with samples from 200-400 individuals from clinically well characterized patients to allow for studies of association between candidate genes and clinical outcome parameters.

Proper citation: KI Biobank - SCI (RRID:SCR_005849) Copy   

•   Source: SciCrunch Registry

http://www.knhi.zks.uni-leipzig.de/en/Research/SP03/

The goal of this project is the creation of an extensive biomaterials bank. Materials (blood, serum, plasma, DNA) from all patients who participate in studies in the network will be collected for this purpose. The objective is a consistently high quality standard for the processing, storage and management of all samples. The biomaterials bank is an investment in the future by the network. It enables the competence network and the research community in general to acquire new scientific knowledge about the development, progression and prognosis of the different forms of heart failure. Each time a patient is documented in a study in the competence network, blood (EDTA whole blood and serum) is drawn from the patient, sent by post to the central biomaterials bank and processed there in the central incoming sample laboratory according to specified standards. In the first two subsidization periods, a total of 100,000 samples from approximately 10,000 patients was documented and processed (aliquoting, DNA extraction). These samples are stored in climate-controlled rooms used especially for this purpose at the biomaterial bank of the Experimental and Clinical Research Center (ECRC) in Berlin-Buch at temperatures between -20 and -80 degrees C. As the central infrastructure project for all samples, the biomaterials bank is deeply involved in the networking. There are also intensive collaborations with other competence networks (e.g. the Competence Network for Congenital Heart Defects) and biobanks. The biomaterial bank of the Heart Failure Competence Network also participates in domestic and European pilot projects for networking biomaterial banks (BBMRI, ESFRI, etc.). The goal of these projects is to develop uniform methods for sample processing and use.

Proper citation: Central Biomaterial Bank - German Heart Failure Network (RRID:SCR_004667) Copy   

•   Source: SciCrunch Registry

http://www.addgene.org/vector-database/

Vector database is a digital collection of vector backbones assembled from publications and commercially available sources. This is a free resource for the scientific community that is compiled by Addgene. Only the plasmids deposited at Addgene are available for purchase through this website.

Proper citation: Vector Database (RRID:SCR_005907) Copy   

•   Source: SciCrunch Registry

http://www.interpore.com/

Biomet and Interpore Cross are on the cutting edge of technology in the orthopedic biomaterials market. Our focus is developing and providing truly innovative products, which meet the rapidly expanding needs of orthopedic surgeons both today and in the future. Our Pro Osteon resorbable bone graft material is derived from an abundant non-decorative coral. Pro Osteon is available in a selection of fully resorbable sterile granules and blocks, in a variety of shapes and sizes. Our InterGro DBM products combine the osteoinductivity of DBM with a natural, non-soluble carrier that won''t wash away, delivering a unique bone graft that offers superior handling and performance characteristics. This highly-moldable composite graft can be easily formed to fit any shape fracture or defect.

Proper citation: Interpore Cross International (RRID:SCR_004776) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103566&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd, 2023. The ICAP - Integrated analysis of prostate cancer study aims at identifying a set of biomarkers with high prognostic value for prostate cancer progression. These biomarkers will be used to customize treatment and to identify patients with high risk of recurrent disease. Sample types: * EDTA whole blood * DNA Number of sample donors: 505 (sample collection completed)

Proper citation: ICAP - Integrated analysis of prostate cancer (RRID:SCR_006035) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103538&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Libro-1 is a study with the overall aim to identify prognostic factors for breast cancer. The study comprise women in the Stockholm-Gotland region that were diagnosed with breast cancer between the years 2001-2008. Register data (tumor characteristics and treatment), lifestyle factors and blood samples have been collected from the participants.

Proper citation: LIBRO-1: Individualized prediction and prevention of breast cancer (RRID:SCR_006036) Copy   

•   Source: SciCrunch Registry

http://cancer.case.edu/research/sharedresources/tissue/services/

A combined tissue bank and core facility which provides annotated human tissue samples for research purposes. The facility also offers high quality tissue procurement, tissue microarray, histology, immunohistochemistry, photomicroscopy, and laser capture microdissection services for both human and animal tissues to biomedical investigators conducting non-clinical research studies. The TPHC offers instruction to researchers on how to incorporate human tissue into research activities and how to work within the boundaries of patient confidentiality and other regulatory issues. The purpose of the TPHC is to provide tissue collection and processing services to intramural and extramural researchers studying cancer and other diseases. Normal, diseased, benign and malignant tissues are obtained, and matched normal adjacent tissues and tissues from different organ sites from the same donor can also be provided when available. Tissue samples are prepared according to user-specified protocols and can be fresh in a medium of choice, fixed in formalin, quick frozen in the vapor phase of liquid nitrogen or snap-frozen by plunging the sample into liquid nitrogen. Frozen tissues are held in the vapor phase of the liquid nitrogen. Tissues can also be embedded, cut and mounted on slides, and stained upon request. Tissue Microarray (TMA) services are offered for the design and construction of TMAs meeting specific project needs. Basic demographic data (age, race, gender) and histopathologic data from Surgical Pathology Reports are provided by the TPHC with the tissues.

Proper citation: Case Western Reserve Tissue Procurement and Histology Core Facility (RRID:SCR_005344) Copy   

•   Source: SciCrunch Registry

http://www.procap.ki.se/procap_studie_info.htm

PROCAP is a study of the importance of lifestyle and genetic factors in the progression of localized cancer of the prostate. Our study hypothesis is that the likelihood of disease recurrence of prostate cancer is modified or determined by genetic variation in the human genome and/or lifestyle factors. To be able to test our hypothesis, we are using a large, population-based cohort of men with localized prostate cancer in Sweden, recruited in 1997-2002, from which detailed clinical information and data on progression already have been collected. From this cohort, we are collecting lifestyle data and blood samples from 8,500 men. If men with progressive prostate cancer could be identified on their genetic make-up, they could be given additional therapies targeted specifically at prostate cancer progression or monitored even more frequently so that progressions could be treated even earlier. If lifestyle factors are important, these results have an impact on recommendations given to men with newly diagnosed prostate cancer. In the study, we are asking the study persons to fill in an Internet-based questionnaire focusing on diet and physical activity and we ask them to leave 2 test tubes of blood at their local urologist/health care center. The pilot study has recently been completed and evaluated and the remaining 7,500 men in the cohort will be included during 2007 and 2008. So far, we have a response rate of approximately 85% on the blood samples. The response rate for the questionnaire is approximately 80% (both in the web based and paper based versions combined). Genotyping and analysis will begin in the fall of 2008. Sample types: * EDTA whole blood * Plasma * DNA Number of sample donors: 5492 (sample collection completed)

Proper citation: KI Biobank - PROCAP (RRID:SCR_006038) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/cancer-of-the-prostate-in-sweden-caps

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. We have completed the recruitment of this population-based prostate cancer case-control study, one of the largest prostate cancer case-control study populations available so far. This study population was recruited in two phases. The inclusion and exclusion criteria were the same for the first (CAPS1) and second phase (CAPS2), except for the timeframe. In total, 3,030 cases and 1,960 controls participated in CAPS donating blood samples and answering a questionnaire during 2001-2003. In addition we have detailed clinical information on all 3,000 cases. With data generated from CAPS we have 25 published papers and 10 manuscripts since 2004. During 2006 we completed a record linkage to the Cause of Death Registry to determine the cause of death for all participants. We could conclude that 347 of the cases in CAPS had died of prostate cancer. The CAPS study has provided data to several new studies on markers on prostate cancer progression. Sample types: * EDTA whole blood * DNA Number of sample donors: 5015 (sample collection completed)

Proper citation: Cancer of the Prostate in Sweden (CAPS) (RRID:SCR_006033) Copy   

•   Source: SciCrunch Registry

http://ki.se/imm/cefalo-studien

Saliva taken from participants in a study investigating the association between environmental exposures and brain tumors in children aged 7-19 years and the interaction between these risk factors and genetic polymorphisms, which may confer susceptibility to effects of exogenous agents. Sample types: * Saliva Number of sample donors: 886 (sample collection completed)

Proper citation: KI Biobank - CEFALO (RRID:SCR_006034) Copy   

•   Source: SciCrunch Registry

http://xgc.nci.nih.gov/

NIH initiative to support production of cDNA libraries, clones and 5'/3' sequences and to provide set of full-length (open reading frame) sequences and cDNA clones of expressed genes for Xenopus laevis and Xenopus tropicalis. Clones distribution is outsourced to for profit companies. Project concluded in September 2008. Resources generated by XGC are publicly accessible to biomedical research community. All sequences are deposited into GenBank.Corresponding clones are available through IMAGE clone distribution network. With conclusion of XGC project, GenBank records of XGC sequences will be frozen, without further updates. Since knowledge of what constitutes full-length coding region for some of genes and transcripts for which we have XGC clones will likely change in future, users planning to order XGC clones will need to monitor for these changes. Users can make use of genome browsers and gene-specific databases, such as UCSC Genome browser, NCBI's Map Viewer, and Entrez Gene, to view relevant regions of genome (browsers) or gene-related information (Entrez Gene).

Proper citation: Xenopus Gene Collection (RRID:SCR_007023) Copy   

•   Source: SciCrunch Registry

http://www.ncri.org.uk/ccb/index.html

The Confederation of Cancer Biobanks (CCB) is a consortium of organisations based in the UK that are involved in the development, management and use of biobank resources for cancer research. The Confederation aims to promote and disseminate a collective view on best practices for biobanks and to promote transfer of knowledge and experiences between banks. While individual banks retain their full autonomy, membership leads to mutual benefit, ensures complementarities, avoids unnecessary competition and ensures a coordinated approach to cancer biosample provision. This will benefit all involved by allowing the sharing of expertise and information, the establishment of harmonized standards for the operation of cancer biobanks and provide a means to access a larger pool of biosamples from the confederated banks. The initial achievements of the NCRI Confederation of Cancer Biobanks were the drafting of a Memorandum of Understanding for the founder members of the Confederation, and a document outlining the Guiding Principles for the management and operation of a tissue bank / biobank in the contemporary ethical and legal setting. Any organization based in the UK, which collects and distributes biosamples for cancer research (not necessarily in the UK), may apply to join. CCB Members receive: * access to the Members Area of the web site containing shared resources * inclusion in email discussion fora with other members * networking opportunities with other members * inclusion in a collective voice to research funders, policy makers, legislators and others * inclusion in the NCRI''s new on-line sample directory * one free registration for each CCB workshop * a future opportunity to pursue accreditation/quality endorsement for the bank * a potential future opportunity for your donors to join a donor forum, which provides patients/sample donors with a mechanism of keeping in touch with research biobanking activities.

Proper citation: Confederation of Cancer Banks (RRID:SCR_006885) Copy   

•   Source: SciCrunch Registry

http://zgc.nci.nih.gov/

Part of zebrafish genome project. ZGC project to produce cDNA libraries, clones and sequences to provide complete set of full-length (open reading frame) sequences and cDNA clones of expressed genes for zebrafish. All ZGC sequences are deposited in GenBank and clones can be purchased from distributors of IMAGE consortium. With conclusion of ZGC project in September 2008, GenBank records of ZGC sequences will be frozen, without further updates. Since definition of what constitutes full-length coding region for some of genes and transcripts for which we have ZGC clones will likely change in future, users planning to order ZGC clones will need to monitor for these changes. Users can make use of genome browsers and gene-specific databases, such as UCSC Genome browser, NCBI's Map Viewer, and Entrez Gene, to view relevant regions of genome (browsers) or gene-related information (Entrez Gene).

Proper citation: Zebrafish Gene Collection (RRID:SCR_007054) Copy   

•   Source: SciCrunch Registry

http://www.alz.washington.edu/

A clinical research, neuropathological research and collaborative research database that uses data collected from 29 NIA-funded Alzheimer's Disease Centers (ADCs). The database consists of several datasets, and searches may be done on the entire database or on individual datasets. Any researcher, whether affiliated with an ADC or not, may request a data file for analysis or aggregate data tables. Requested aggregate data tables are produced and returned as soon as the queue allows (usually within 1-3 days depending on the complexity).

Proper citation: National Alzheimer's Coordinating Center (RRID:SCR_007327) Copy   

•   Source: SciCrunch Registry

http://www.sanger.ac.uk/mouseportal/

Database of mouse research resources at Sanger: BACs, targeting vectors, targeted ES cells, mutant mouse lines, and phenotypic data generated from the Institute''''s primary screen. The Wellcome Trust Sanger Institute generates, characterizes, and uses a variety of reagents for mouse genetics research. It also aims to facilitate the distribution of these resources to the external scientific community. Here, you will find unified access to the different resources available from the Institute or its collaborators. The resources include: 129S7 and C57BL6/J bacterial artificial chromosomes (BACs), MICER gene targeting vectors, knock-out first conditional-ready gene targeting vectors, embryonic stem (ES) cells with gene targeted mutations or with retroviral gene trap insertions, mutant mouse lines, and phenotypic data generated from the Institute''''s primary screen.

Proper citation: Sanger Mouse Resources Portal (RRID:SCR_006239) Copy   

•   Source: SciCrunch Registry